An Observational Cohort to Assess Safety and Outcomes in Patients Treated With Abatacept and Other Anti-Rheumatic Therapies
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Nov 2018
At a glance
- Drugs Abatacept (Primary) ; Disease-modifying antirheumatics; Tumour necrosis factor inhibitors
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 30 Oct 2018 Planned End Date changed from 30 Sep 2019 to 30 Oct 2019.
- 30 Oct 2018 Planned primary completion date changed from 30 Sep 2019 to 30 Oct 2019.
- 07 Aug 2017 Planned End Date changed from 31 Aug 2017 to 30 Sep 2019.